Monograph
M09AB02 - Collagenase Clostridium Histolyticum |
Not porphyrinogenic |
NP |
Rationale
Collagenase clostridum histolyticum is not a substrate of CYP450 enzymes.
Risk for gastrointestinal adverse events in the form of nausea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Therapeutic characteristics
It is indicated for the treatment of Dupuytrens contracture.
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are is nausea. Other common side effects are pain in the extremities, arthralgia and myalgia. Less common side effects are diarrhoea, vomiting and abdominal pain.
Metabolism and pharmacokinetics
Collagenase clostridum histolyticum is not a substrate of CYP450 enzymes (SPC).
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Xiapex.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Norway© NAPOS 2024